UBX · Unity Biotechnology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.77M | - | $2.79M | $3.46M | $3.72M | - | $4.90M | $6.53M | $5.83M | - |
| SG&A | $4.12M | - | $3.81M | $3.52M | $3.88M | - | $4.43M | $5.43M | $4.82M | - |
| Total Operating Expenses | $6.89M | - | $6.60M | $6.98M | $7.60M | - | $14.93M | $11.96M | $10.65M | - |
| D&A | $178.0K | - | - | - | $227.0K | - | - | - | $329.0K | - |
| Operating Income | ($6.89M) | - | ($6.60M) | ($6.98M) | ($7.60M) | - | ($14.93M) | ($11.96M) | ($10.65M) | - |
| Interest Expense | - | - | - | - | $0 | - | $470.0K | $979.0K | $1.00M | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($7.30M) | - | ($6.48M) | ($5.28M) | ($5.79M) | - | ($15.29M) | ($12.21M) | ($10.87M) | - |
| EPS - Basic | ($0.43) | - | ($0.38) | ($0.31) | ($0.34) | - | ($1.05) | ($0.85) | ($2.80) | - |
| EPS - Diluted | ($0.43) | - | ($0.38) | ($0.31) | ($0.34) | - | ($1.05) | ($0.85) | ($0.76) | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.00M | $7.58M | $8.90M | $7.58M | $7.43M | $19.80M | $7.88M | $19.12M | $22.97M | $12.74M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.76M | $997.0K | $1.80M | $1.46M | $1.40M | $1.38M | $1.15M | $1.45M | $1.47M | $1.79M |
| Current Assets | $17.65M | $24.27M | $30.26M | $35.85M | $38.52M | $46.60M | $49.54M | $72.97M | $86.38M | $96.53M |
| Total Assets | $30.35M | $37.66M | $47.13M | $53.52M | $58.86M | $65.69M | $69.27M | $101.01M | $114.25M | $124.35M |
| Current Liabilities | $9.07M | $9.26M | $8.78M | $8.82M | $7.73M | $7.84M | $8.63M | $22.22M | $21.86M | $19.62M |
| Long-term Debt | - | - | - | - | - | $0 | $0 | $4.08M | $7.62M | $10.89M |
| Total Liabilities | $30.55M | $31.17M | $32.99M | $33.77M | $34.88M | $37.29M | $33.06M | $51.60M | $55.63M | $57.50M |
| Stockholders' Equity | ($205.0K) | $6.49M | $14.14M | $19.75M | $23.99M | $28.40M | $36.21M | $49.41M | $58.63M | $66.85M |
| Retained Earnings | ($517.64M) | ($510.34M) | ($501.90M) | ($495.42M) | ($490.14M) | ($484.35M) | ($498.31M) | ($483.02M) | ($470.82M) | ($459.95M) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.36M) | - | - | - | ($5.18M) | - | - | - | ($11.32M) | - |
| Investing Cash Flow | $6.78M | - | - | - | ($7.19M) | - | - | - | $21.28M | - |
| Financing Cash Flow | - | - | - | - | $0 | - | - | - | $274.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -24.1% | - | -13.8% | -9.9% | -9.8% | - | -22.1% | -12.1% | -9.5% | - |
| Return on equity | 3562.0% | - | -45.8% | -26.7% | -24.1% | - | -42.2% | -24.7% | -18.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.95 | 2.62 | 3.45 | 4.07 | 4.98 | 5.94 | 5.74 | 3.28 | 3.95 | 4.92 |
| Quick ratio | 1.95 | 2.62 | 3.45 | 4.07 | 4.98 | 5.94 | 5.74 | 3.28 | 3.95 | 4.92 |
| Cash ratio | 0.88 | 0.82 | 1.01 | 0.86 | 0.96 | 2.53 | 0.91 | 0.86 | 1.05 | 0.65 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | 0.00 | 0.00 | 0.08 | 0.13 | 0.16 |
| Debt / Assets | - | - | - | - | - | 0.00 | 0.00 | 0.04 | 0.07 | 0.09 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | -31.8x | -12.2x | -10.6x | - |
| Equity multiplier | -148.03 | 5.80 | 3.33 | 2.71 | 2.45 | 2.31 | 1.91 | 2.04 | 1.95 | 1.86 |
| Liabilities / Assets | 1.01 | 0.83 | 0.70 | 0.63 | 0.59 | 0.57 | 0.48 | 0.51 | 0.49 | 0.46 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 9.3% | - | 55.8% | 41.7% | 28.7% | - | -13.7% | 2.4% | 41.7% | - |
| Net income growth (YoY) | -26.1% | - | 57.6% | 56.7% | 46.7% | - | -11.5% | 7.1% | 42.6% | - |
| EPS growth (YoY) | -26.5% | - | 63.8% | 63.5% | 55.3% | - | 22.8% | -347.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -77.1% | -60.9% | -60.0% | -59.1% | -57.5% | -53.9% | 23.7% | 15.7% | 12.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Unity Biotechnology against the 5 most active filers in the same SIC group.